We will not have to sell one more share in private placement.
posted previously*********
Future ARCH Financings
I am beginning to doubt whether there will be any future stock financings in light of what I am seeing in recent JV deals.
I see people are attempting to talk the Arch price down talking about stock financings. Look they had $ 5.7 million cash per recent 10-Q. I believe another $ 1.9 series E warrants were exercised recently. They burn $400,000 month. Thus 17 months of funding.
Study these and note size of numbers and dream about ARTH. Imagine if they did a deal for just 50 of the 200 potential applications.
Remember we only need $ 8 to $ 12 million of additional capital to get all the human trials in Europe AND USA per SEC filings. This is SMALL. A JV in Europe could take care of this easily.
Study these recent deals to see how big the numbers have gotten:
Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study (market cap $ 67 million—royalty in high teens)
“This morning, MEI $MEIP is taking the wraps off a development deal with Switzerland’s Helsinn designed to shepherd the HDAC inhibitor pracinostat through a pivotal study. MEI gets $20 million in near-term cash —$15 million up front with a $5 million milestone at the start of the Phase III — along with a $5 million equity investment. And there’s $444 million in milestones on the table for success, along with royalties that can be earned from Helsinn’s marketing efforts”
“Advaxis Inc. ADXS, +5.48% shares spiked 28% in pre-market trade Tuesday after the company announced a $40 million agreement with Amgen Inc. AMGN, -0.15% to develop and commercialize cancer immunotherapy treatment ADXS-NEO. The agreement includes a $40 million upfront payment to Advaxis and a $25 million purchase of the company’s common stock by Amgen, along with sales milestone payments of up to $475 million and additional royalty payments based on global sales.
News 
Market Data 
Discover 
AI
